达格列净对心血管疾病的预防保护机制  

Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease

作　　者：耿肖囡 肖东斌 魏鑫 惠学志 GENG Xiaonan;XIAO Dongbin;WEI Xin;HUI Xuezhi(Henan University Graduate School,Kaifeng 475000,Henan,China;Department of Cardiology,The First Affiliated Hospital of Henan University,Kaifeng 475000,Henan,China)

机构地区：[1]河南大学研究生院,河南开封475000 [2]河南大学第一附属医院心血管内科,河南开封475000

出　　处：《心血管病学进展》2019年第8期1169-1171,共3页Advances in Cardiovascular Diseases

摘　　要：钠-葡萄糖协同转运蛋白2抑制剂是一种新型的降糖药物,其抑制钠-葡萄糖协同转运蛋白2的作用机制不同于以往的降血糖药物。以达格列净为代表的该类药物在降低血糖的同时兼具降脂、降压、肾脏保护等多方面的获益,达格列净可在一定程度上干预降低2型糖尿病患者心血管事件的发生和发展。其在降血糖以外对心血管的保护作用方面展现出特殊的优势,现就钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者的心血管保护和心血管事件危险因素的预防机制做一综述。The sodium-glucose cotransporter 2(SGLT-2)inhibitor is a novel hypoglycemic agent,and its role mechanism of inhibiting SGLT-2 is different from previous hypoglycemic agents.This type of drug,represented by dagliflozin,has both benefits in reducing blood sugar and benefits such as reducing fat,reducing blood pressure,and protecting the kidneys.Dagliflozin can intervene to reduce the incidence and development of cardiovascular events in patients with type 2 diabetes to some extent.It has a special advantage in protecting the cardiovascular system from hypoglycemia.This article reviews the effect of SGLT-2 inhibitor in cardiovascular protection and the prevention mechanism of cardiovascular risk factors for type 2 diabetes patients.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 达格列净 心血管疾病 2型糖尿病 

分 类 号：R58[医药卫生—内分泌]